PMID- 16515857
OWN - NLM
STAT- MEDLINE
DCOM- 20060711
LR  - 20181201
IS  - 0920-1211 (Print)
IS  - 0920-1211 (Linking)
VI  - 69
IP  - 2
DP  - 2006 May
TI  - Relationship between serum mono-hydroxy-carbazepine concentrations and adverse 
      effects in patients with epilepsy on high-dose oxcarbazepine therapy.
PG  - 170-6
AB  - PURPOSE: To investigate the relationship between the serum concentration of the 
      mono-hydroxy-derivative (MHD) of oxcarbazepine (OXC) and adverse effects (AEs) in 
      epileptic patients on high-dose OXC therapy. PATIENTS AND METHODS: Forty-four 
      consecutive patients, aged 18-65 years, with refractory epilepsy receiving OXC 
      dosages > or = 1500 mg/day (range 1500-3300 mg/day) were assessed at an 
      outpatient clinic. Serum MHD concentrations were determined by a specific HPLC 
      assay in samples collected before the morning dose and 2 h after drug intake. An 
      independent observer assessed AEs at each sampling time. RESULTS: AEs were 
      reported in five patients at the first sampling time, and in 26 patients at the 
      second sampling time. Nystagmus, sedation, blurred vision, and dizziness were the 
      most frequent AEs. MHD concentrations (means +/- S.D.) associated with AEs were 
      29.6 +/- 5.58 compared with 21.7 +/- 5.0 mg/L when no AEs were detected (p = 
      0.0001). AEs were minimized in most patients by reducing OXC dose, increasing the 
      number of daily administrations, or both. CONCLUSION: Patients with serum MHD 
      concentrations > or = 30 mg/L are at greater risk of developing AEs. In many 
      patients, AEs occur intermittently in relation to fluctuations in serum MHD. 
      Monitoring MHD concentrations could help in the management of patients on 
      high-dose OXC therapy.
FAU - Striano, Salvatore
AU  - Striano S
AD  - Epilepsy Center, Department of Neurological Sciences, Federico II University, 
      Naples, Italy. sstriano@libero.it
FAU - Striano, Pasquale
AU  - Striano P
FAU - Di Nocera, Pierpaolo
AU  - Di Nocera P
FAU - Italiano, Domenico
AU  - Italiano D
FAU - Fasiello, Cecilia
AU  - Fasiello C
FAU - Ruosi, Patrizia
AU  - Ruosi P
FAU - Bilo, Leonilda
AU  - Bilo L
FAU - Pisani, Francesco
AU  - Pisani F
LA  - eng
PT  - Journal Article
DEP - 20060303
PL  - Netherlands
TA  - Epilepsy Res
JT  - Epilepsy research
JID - 8703089
RN  - 0 (10,11-dihydro-10-hydroxycarbamazepine)
RN  - 0 (Anticonvulsants)
RN  - 33CM23913M (Carbamazepine)
RN  - VZI5B1W380 (Oxcarbazepine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anticonvulsants/administration & dosage/*adverse effects/metabolism
MH  - Carbamazepine/administration & dosage/adverse effects/*analogs & 
      derivatives/blood/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Epilepsy/blood/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxcarbazepine
EDAT- 2006/03/07 09:00
MHDA- 2006/07/13 09:00
CRDT- 2006/03/07 09:00
PHST- 2005/10/05 00:00 [received]
PHST- 2006/01/17 00:00 [revised]
PHST- 2006/01/25 00:00 [accepted]
PHST- 2006/03/07 09:00 [pubmed]
PHST- 2006/07/13 09:00 [medline]
PHST- 2006/03/07 09:00 [entrez]
AID - S0920-1211(06)00058-1 [pii]
AID - 10.1016/j.eplepsyres.2006.01.011 [doi]
PST - ppublish
SO  - Epilepsy Res. 2006 May;69(2):170-6. doi: 10.1016/j.eplepsyres.2006.01.011. Epub 
      2006 Mar 3.